Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before ...
Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
Exelixis, Inc. ( NASDAQ:EXEL ) recently posted some strong earnings, and the market responded positively. We did ...
BioSpace3d
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...
FiercePharma4d
As BMS-paired triplet misses survival mark in kidney cancer, Exelixis shifts focus elsewhere
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...
Exelixis announces final five-year follow-up results from CheckMate -9ER
Exelixis (EXEL) announced final results from the phase 3 CheckMate -9ER pivotal trial evaluating Cabometyx in combination with Opdivo versus ...
Nasdaq2d
Exelixis Approves Additional $500 Mln Stock Buyback Program
(RTTNews) - Exelixis, Inc. (EXEL) Thursday announced that its Board of Directors has authorized an additional $500 million stock repurchase program, set to run through December 31. The company ...
Barclays Sticks to Its Hold Rating for Exelixis (EXEL)
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target of ...
Exelixis (NASDAQ:EXEL) Stock Price Expected to Rise, Barclays Analyst Says
Exelixis (NASDAQ:EXEL – Free Report) had its price target increased by Barclays from $25.00 to $29.00 in a report released on Thursday morning,Benzinga reports. They currently have an equal weight ...
Exelixis (NASDAQ:EXEL) Receives Buy Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $40.00 ...